Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

408 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
FDG-PET/CT based response-adapted treatment.
de Geus-Oei LF, Vriens D, Arens AI, Hutchings M, Oyen WJ. de Geus-Oei LF, et al. Among authors: hutchings m. Cancer Imaging. 2012 Sep 28;12(2):324-35. doi: 10.1102/1470-7330.2012.9006. Cancer Imaging. 2012. PMID: 23023063 Free PMC article. Review.
Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study.
Kersten MJ, Driessen J, Zijlstra JM, Plattel WJ, Morschhauser F, Lugtenburg PJ, Brice P, Hutchings M, Gastinne T, Liu R, Burggraaff CN, Nijland M, Tonino SH, Arens AIJ, Valkema R, van Tinteren H, Lopez-Yurda M, Diepstra A, De Jong D, Hagenbeek A. Kersten MJ, et al. Among authors: hutchings m. Haematologica. 2021 Apr 1;106(4):1129-1137. doi: 10.3324/haematol.2019.243238. Haematologica. 2021. PMID: 32273476 Free PMC article. Clinical Trial.
Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP.
Driessen J, Kersten MJ, Visser L, van den Berg A, Tonino SH, Zijlstra JM, Lugtenburg PJ, Morschhauser F, Hutchings M, Amorim S, Gastinne T, Nijland M, Zwezerijnen GJC, Boellaard R, de Vet HCW, Arens AIJ, Valkema R, Liu RDK, Drees EEE, de Jong D, Plattel WJ, Diepstra A; HOVON Lunenburg Lymphoma Phase I/II Consortium (LLPC). Driessen J, et al. Among authors: hutchings m. Leukemia. 2022 Dec;36(12):2853-2862. doi: 10.1038/s41375-022-01717-8. Epub 2022 Oct 14. Leukemia. 2022. PMID: 36241696
Employment situation among long-term Hodgkin lymphoma survivors in Europe: an analysis of patients from nine consecutive EORTC-LYSA trials.
Juul SJ, Rossetti S, Kicinski M, van der Kaaij MAE, Giusti F, Meijnders P, Aleman BMP, Raemaekers JMM, Kluin-Nelemans HC, Spina M, Fermé C, Renaud L, Casasnovas O, Stamatoullas A, André M, Le Bras F, Plattel WJ, Henry-Amar M, Hutchings M, Maraldo MV. Juul SJ, et al. Among authors: hutchings m. J Cancer Surviv. 2024 Jun;18(3):727-738. doi: 10.1007/s11764-022-01305-w. Epub 2022 Nov 28. J Cancer Surviv. 2024. PMID: 36441393
Work and education interruption in long-term Hodgkin lymphoma survivors: an analysis among patients from nine EORTC-LYSA trials.
Juul SJ, Rossetti S, Kicinski M, van der Kaaij MAE, Giusti F, Meijnders P, Aleman BMP, Raemaekers JMM, Kluin-Nelemans HC, Spina M, Fermé C, Renaud L, Casasnovas O, Stamatoullas A, André M, Le Bras F, Plattel WJ, Henry-Amar M, Hutchings M, Maraldo MV. Juul SJ, et al. Among authors: hutchings m. Acta Oncol. 2023 Jul;62(7):744-752. doi: 10.1080/0284186X.2023.2195561. Epub 2023 Apr 11. Acta Oncol. 2023. PMID: 37039661 Clinical Trial.
Long-Term Follow-Up of the Response-Adapted Intergroup EORTC/LYSA/FIL H10 Trial for Localized Hodgkin Lymphoma.
Federico M, Fortpied C, Stepanishyna Y, Gotti M, van der Maazen R, Cristinelli C, Re A, Plattel W, Lazarovici J, Merli F, Specht L, Schiano de Colella JM, Hutchings M, Versari A, Edeline V, Stamatoulas A, Girinsky T, Ricardi U, Aleman B, Meulemans B, Tonino S, Raemaekers J, André M. Federico M, et al. Among authors: hutchings m. J Clin Oncol. 2024 Jan 1;42(1):19-25. doi: 10.1200/JCO.23.01745. Epub 2023 Nov 15. J Clin Oncol. 2024. PMID: 37967311 Clinical Trial.
Reply to T. Vassilakopoulos et al.
Federico M, Plattel W, Hutchings M, Stepanishyna Y, Fortpied C, André M. Federico M, et al. Among authors: hutchings m. J Clin Oncol. 2024 Apr 9:JCO2400143. doi: 10.1200/JCO.24.00143. Online ahead of print. J Clin Oncol. 2024. PMID: 38593392 No abstract available.
Targeted immunotherapy in Hodgkin lymphoma.
Hutchings M. Hutchings M. Blood. 2015 Jun 25;125(26):3967-8. doi: 10.1182/blood-2015-05-641712. Blood. 2015. PMID: 26113529 Free article.
FDG-PET in the clinical management of Hodgkin lymphoma.
Hutchings M, Eigtved AI, Specht L. Hutchings M, et al. Crit Rev Oncol Hematol. 2004 Oct;52(1):19-32. doi: 10.1016/j.critrevonc.2004.05.007. Crit Rev Oncol Hematol. 2004. PMID: 15363464 Review.
408 results